Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 458 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Acurx Pharmaceuticals, Inc.
Market Cap
$5.63M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.54M
Net Profit Margin
-294.91%
TTM Avg
-320.57%
3Y Avg
-453.36%
5Y Avg
-361.46%
Market Cap
$5.36M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.03M
Net Profit Margin
-9366.75%
TTM Avg
-6298.14%
3Y Avg
-3910.26%
5Y Avg
-3305.87%
Market Cap
$5.21M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1794.91%
5Y Avg
-2605.04%
Market Cap
$6.09M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-86.55%
Market Cap
$6.10M
Net Profit Margin
-44771.83%
TTM Avg
-33930.36%
3Y Avg
-151894.64%
5Y Avg
-112740.11%
Market Cap
$6.10M
Net Profit Margin
-534.27%
TTM Avg
-983.65%
3Y Avg
-1060.24%
5Y Avg
-924.37%
Market Cap
$4.99M
Net Profit Margin
-4011.86%
TTM Avg
-2005.93%
3Y Avg
-2671.67%
5Y Avg
-1781.12%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | $5.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.54M | -294.91% | -320.57% | -453.36% | -361.46% |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.03M | -9366.75% | -6298.14% | -3910.26% | -3305.87% |
| Imunon, Inc. (IMNN)vs › | $5.21M | 0.00% | 0.00% | -1794.91% | -2605.04% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | 0.00% | 0.00% | 0.00% | -86.55% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | -44771.83% | -33930.36% | -151894.64% | -112740.11% |
| Femasys Inc. (FEMY)vs › | $6.10M | -534.27% | -983.65% | -1060.24% | -924.37% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | -4011.86% | -2005.93% | -2671.67% | -1781.12% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | -106.78% | -43.08% | -12.30% | -12.30% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
